Deverra Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$979K
- Investors
-
4
Deverra Therapeutics General Information
Description
Developer of a biotechnology platform designed to generate off-the-shelf allogeneic cellular immunotherapies. The company's platform helps in the production of progenitor blood and immune cells for clinical application to treat cancer and infectious diseases, enabling patients suffering from hematologic malignancies and other critical diseases to be cured.
Contact Information
Website
www.deverratx.comCorporate Office
- 1600 Fairview Avenue East
- Suite 300
- Seattle, WA 98102
- United States
Corporate Office
- 1600 Fairview Avenue East
- Suite 300
- Seattle, WA 98102
- United States
Deverra Therapeutics Timeline
Deverra Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Equity Crowdfunding | 04-Sep-2024 | $979K | Completed | Clinical Trials - Phase 1 | ||
| 4. Early Stage VC | 18-Sep-2023 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 01-Sep-2023 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 27-Aug-2020 | $75K | $75K | Completed | Startup | |
| 1. Early Stage VC | 01-Jan-2019 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Deverra Therapeutics Patents
Deverra Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023338109-A1 | Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells | Pending | 07-Sep-2022 | ||
| EP-4583891-A1 | Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells | Pending | 07-Sep-2022 | ||
| EP-4583891-A4 | Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells | Pending | 07-Sep-2022 | ||
| US-20260355236-A1 | Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells | Pending | 07-Sep-2022 | ||
| WO-2024054769-A1 | Methods for the generation of a monocyte/macrophage cell product from expanded cord blood cd34+ hematopoietic stem and progenitor cells | Inactive | 07-Sep-2022 | A61K40/17 |
Deverra Therapeutics Signals
Deverra Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| D3VC | Venture Capital | Minority | ||
| Andy Hill Care Fund | Government | |||
| 5AM Ventures | Venture Capital | Minority | ||
| Sorrento Therapeutics | Corporation | Minority |
Deverra Therapeutics FAQs
-
When was Deverra Therapeutics founded?
Deverra Therapeutics was founded in 2019.
-
Where is Deverra Therapeutics headquartered?
Deverra Therapeutics is headquartered in Seattle, WA.
-
What is the size of Deverra Therapeutics?
Deverra Therapeutics has 14 total employees.
-
What industry is Deverra Therapeutics in?
Deverra Therapeutics’s primary industry is Biotechnology.
-
Is Deverra Therapeutics a private or public company?
Deverra Therapeutics is a Private company.
-
What is the current valuation of Deverra Therapeutics?
The current valuation of Deverra Therapeutics is .
-
What is Deverra Therapeutics’s current revenue?
The current revenue for Deverra Therapeutics is .
-
How much funding has Deverra Therapeutics raised over time?
Deverra Therapeutics has raised $3.44M.
-
Who are Deverra Therapeutics’s investors?
D3VC, Andy Hill Care Fund, 5AM Ventures, and Sorrento Therapeutics have invested in Deverra Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process